Expert Point of View: Charles E. Geyer, Jr, MD, FACP

Get Permission

Charles E. Geyer, Jr, MD, FACP

I really feel this should put to rest any concerns that surgeons might have about neoadjuvant chemotherapy.

—Charles E. Geyer, Jr, MD, FACP

Discussant Charles E. Geyer, Jr, MD, FACP, Associate Director for Clinical Research at Virginia Commonwealth University Massey Cancer Center in Richmond, Virginia, singled out the power of this study’s dataset. “In 2002,” he said, “the Institute of Medicine named NSQIP [National Surgical Quality Improvement Program] the ‘best in the nation’ for measuring and reporting surgical quality and outcomes….  To me, this elevates this study because the data are coming from a very strong, validated dataset.”

Dr. Geyer also noted that although there were differences between groups in the unadjusted data, the 30-day morbidity rate for patients receiving neoadjuvant chemotherapy was still very positive.

“You see low numbers of infections, low bleeding complications, and when you do the adjustments, you see that neoadjuvant chemotherapy does not increase risk,” concluded Dr. Geyer. “I really feel this should put to rest any concerns that surgeons might have about neoadjuvant chemotherapy.” ■

Disclosure: Dr. Geyer reported no potential conflicts of interest.


Related Articles

Neoadjuvant Chemotherapy Appears to Have No Effect on Short-Term Outcomes in Breast Cancer Surgery

Patients who received neoadjuvant chemotherapy within 30 days prior to breast cancer surgery did not appear to be at increased risk for overall postoperative complications, according to a study presented at the 2015 Breast Cancer Symposium.1

“Although on unadjusted analysis there were more...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.